{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:11:15Z","timestamp":1783905075122,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,12]]},"DOI":"10.7759\/cureus.112523","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:16Z","timestamp":1783903156000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Mahmoud","family":"Alzahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najlaa","family":"Alsudairy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Al Asmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujainah","family":"Basubrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah","family":"Abdullatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyad","family":"Alawashiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Alrezqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023458","article-title":"Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis","volume":"9","author":"Kanters S","year":"2019","unstructured":"Kanters S, Wilkinson L, Vrazic H, Sharma R, Lopes S, Popoff E, Druyts E. Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis. BMJ Open. 2019, 9:e023458. 10.1136\/bmjopen-2018-023458","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01721-y","article-title":"Once-weekly semaglutide versus sodium-glucose co-transporter 2 inhibitors: real-world impact on weight, HbA1c, and healthcare resource utilization in type 2 diabetes (PAUSE)","volume":"16","author":"Amamoo J","year":"2025","unstructured":"Amamoo J, Doshi R, Noone J, et al.. Once-weekly semaglutide versus sodium-glucose co-transporter 2 inhibitors: real-world impact on weight, HbA1c, and healthcare resource utilization in type 2 diabetes (PAUSE). Diabetes Ther. 2025, 16:1033-48. 10.1007\/s13300-025-01721-y","journal-title":"Diabetes Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13978","article-title":"Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial","volume":"22","author":"Blonde L","year":"2020","unstructured":"Blonde L, Belousova L, Fainberg U, et al.. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2020, 22:929-37. 10.1111\/dom.13978","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838887","article-title":"Combination therapy with semaglutide and dapagliflozin as an effective approach for the management of type A insulin resistance syndrome: a case report","volume":"13","author":"Mart\u00ednez-Montoro JI","year":"2022","unstructured":"Mart\u00ednez-Montoro JI, Pinz\u00f3n-Mart\u00edn JL, Damas-Fuentes M, Fern\u00e1ndez-Valero A, Tinahones FJ. Combination therapy with semaglutide and dapagliflozin as an effective approach for the management of type A insulin resistance syndrome: a case report. Front Endocrinol (Lausanne). 2022, 13:838887. 10.3389\/fendo.2022.838887","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas A","year":"2020","unstructured":"Tsapas A, Avgerinos I, Karagiannis T, et al.. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020, 173:278-86. 10.7326\/M20-0864","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105782","article-title":"Anti-diabetic drugs and weight loss in patients with type 2 diabetes","volume":"171","author":"Lazzaroni E","year":"2021","unstructured":"Lazzaroni E, Ben Nasr M, Loretelli C, et al.. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021, 171:105782. 10.1016\/j.phrs.2021.105782","journal-title":"Pharmacol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-023-00943-3","article-title":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","volume":"6","author":"Dwibedi C","year":"2024","unstructured":"Dwibedi C, Ekstr\u00f6m O, Brandt J, Adiels M, Franz\u00e9n S, Abrahamsson B, Rosengren AH. Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nat Metab. 2024, 6:50-60. 10.1038\/s42255-023-00943-3","journal-title":"Nat Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Tsapas A","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, et al.. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021, 23:2116-24. 10.1111\/dom.14451","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14141475","article-title":"New insights on using oral semaglutide versus dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Stratina E","year":"2024","unstructured":"Stratina E, Stanciu C, Nastasa R, et al.. New insights on using oral semaglutide versus dapagliflozin in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Diagnostics (Basel). 2024, 14:1475. 10.3390\/diagnostics14141475","journal-title":"Diagnostics (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis M","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025, 77:100002. 10.1124\/pharmrev.123.001045","journal-title":"Pharmacol Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1138499","article-title":"Hypoglycemic medicines in the treatment of Alzheimer's disease: pathophysiological links between AD and glucose metabolism","volume":"14","author":"Wang Y","year":"2023","unstructured":"Wang Y, Hu H, Liu X, Guo X. Hypoglycemic medicines in the treatment of Alzheimer's disease: pathophysiological links between AD and glucose metabolism. Front Pharmacol. 2023, 14:1138499. 10.3389\/fphar.2023.1138499","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107040","article-title":"Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide","volume":"199","author":"Lunati ME","year":"2024","unstructured":"Lunati ME, Cimino V, Bernasconi D, et al.. Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res. 2024, 199:107040. 10.1016\/j.phrs.2023.107040","journal-title":"Pharmacol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200909142126","article-title":"Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes","volume":"27","author":"Papazafiropoulou AK","year":"2021","unstructured":"Papazafiropoulou AK, Melidonis A, Antonopoulos S. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes. Curr Pharm Des. 2021, 27:1035-42. 10.2174\/1381612826666200909142126","journal-title":"Curr Pharm Des"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13743","article-title":"Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials","volume":"21","author":"Giugliano D","year":"2019","unstructured":"Giugliano D, De Nicola L, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes Obes Metab. 2019, 21:1790-800. 10.1111\/dom.13743","journal-title":"Diabetes Obes Metab"},{"key":"ref15","unstructured":"Raosoft sample size calculator. (2026). Accessed. June 1, 2026: https:\/\/raosoftcalculator.com\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/512513-effectiveness-and-safety-of-combined-semaglutide-and-dapagliflozin-therapy-in-type-2-diabetes-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:39:17Z","timestamp":1783903157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/512513-effectiveness-and-safety-of-combined-semaglutide-and-dapagliflozin-therapy-in-type-2-diabetes-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.112523","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,12]]}}}